Equities Research Analysts’ Updated EPS Estimates for March, 20th (CCLAY, CDAY, CDLX, CDXC, CHCT, CKPT, CMFN, COHU, COIHY, COLL)

Share on StockTwits

Equities Research Analysts’ updated eps estimates for Wednesday, March 20th:

COCA COLA AMATI/ADR (OTCMKTS:CCLAY) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Coca-Cola Amatil limited’s principal activity is the manufacture, distribution and marketing of non-alcoholic ready to drink beverages which include carbonated and non carbonated drinks which include mineral and bottled waters, ready-to-drink coffee and tea, juices/nectar, sport drinks, fruit still drinks, energy drinks, other ready-to-drink beverages and flavoured milk drinks. Major brands include Coca-Cola, diet Coke, Coca-Cola Light, Fanta, Sprite, Lift, Lift Plus, POWERaDE, Mount Franklin, Fruitopia, pump, L&P, Deep Spring, Schweppes, Qoo, Kin Cider, and Nescafe. “

Ceridian HCM (NYSE:CDAY) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Ceridian HCM Holding Inc. provides human capital management software company. It provides human resources, payroll, benefits, workforce management and talent management functionality. Ceridian HCM Holding Inc. is based in Minneapolis, United States. “

Cardlytics (NASDAQ:CDLX) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Cardlytics, Inc. is engaged in developing a purchase intelligence platform. The purchase data includes debit, credit and bill pay data from online and in-store transactions. It helps the marketers identify, reach and influence likely buyers at scale, and measure the impact of marketing spends. The Company also operates an advertising channel, Cardlytics Direct. Cardlytics Direct delivers tailored marketing for marketers and financial institutions. Cardlytics, Inc. is based in ATLANTA, United States. “

Chromadex (NASDAQ:CDXC) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “ChromaDex Corporation and its subsidiaries supply phytochemical reference standards and reference materials, related contract services, and products for the dietary supplement, nutraceutical, food and beverage, functional food, pharmaceutical and cosmetic markets. ChromaDex’s core business strategy is to use the intellectual property harnessed by its expertise in the area of natural products and in the creation of reference materials to the industry as the basis for providing new and alternative, green, mass marketable products to its customers. The Company’s main priority is to create industry-accepted information, and to provide products and services to every layer of the functional food, pharmaceutical, personal care and dietary supplement markets. The company markets and sells its products in the United States and Canada. It offers its products through distributors in Europe, South America, Korea, India, Japan, Australia, New Zealand, China, Indonesia, Malaysia, Singapore, Thailand, and Mexico. “

Community Healthcare Trust (NYSE:CHCT) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Community Healthcare Trust Incorporated is engaged in the acquisition of properties which are leased to hospitals, doctors, healthcare systems or other healthcare service providers. Community Healthcare Trust Incorporated is based in Franklin, United States. “

Checkpoint Therapeutics (NASDAQ:CKPT) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $3.50 target price on the stock. According to Zacks, “Checkpoint Therapeutics, Inc. is a clinical stage, immuno oncology biopharmaceutical. It focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Checkpoint Therapeutics, Inc. is headquartered in New York City. “

CM Finance (NASDAQ:CMFN) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “CM Finance Inc. is an externally managed, closed-end, non-diversified management investment company. It invests primarily in middle-market companies in the U.S. The company invest through unitranche loans and standalone second and first lien loans with an emphasis on floating rate debt as well as in mezzanine loans/structured equity and in the equity of portfolio companies. CM Finance Inc. is based in New York, United States. “

Cohu (NASDAQ:COHU) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Cohu is a leading supplier of semiconductor test and inspection handlers, micro-electro mechanical system (MEMS) test modules, test contactors and thermal sub-systems used by global semiconductor manufacturers and test subcontractors. “

CRODA INTL PLC/ADR (OTCMKTS:COIHY) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Croda International plc engages in the manufacture and distribution of specialty chemicals. Its operating segment consists of Personal Care, Life Sciences, Performance Technologies and Industrial Chemicals. Personal Care segment offers ingredients for the personal care industry such as skin care, sun care, hair care, colour cosmetics and toiletries. Life Sciences segment comprises the health care business, which delivers ingredients and formulation expertise to pharmaceutical and nutritional markets and the crop care business which provides ingredients and formulation expertise to agrochemical companies. Performance Technologies segment includes lubricants, coatings and polymers, geo technologies, polymer additives and home care. Industrial Chemicals segment provides bio-based phase change material for thermal management, dispersants and additives for catalysts, electronics and advance ceramics. Croda International plc is headquartered in Goole, the United Kingdom. “

Collegium Pharmaceutical (NASDAQ:COLL) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Collegium Pharmaceutical Inc. is a specialty pharmaceutical company. It develops and commercializes prescription and over-the-counter pharmaceuticals for the treatment of central nervous system, respiratory and skin related disorders. The Company’s product candidate consists of COL-195, COL-196, COL-171, COL-003 and COL-172 which are in different clinical trial. It developed a formulation platform technology, DETERx, for the treatment of chronic pain. Collegium Pharmaceutical Inc. is based in CUMBERLAND, United States. “

CRH Medical (NYSEAMERICAN:CRHM) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “CRH Medical Corporation offers products and services to physicians for the treatment of gastrointestinal diseases primarily in the United States. The company provides the CRH O’Regan System, a single use, disposable and hemorrhoid banding technology for treating hemorrhoid grades I – IV. It distributes the CRH O’Regan System, treatment protocols, operational and marketing expertise as a complete, turnkey package directly to physicians. The company utilizes Web-based platform to connect doctors with patients as well as educating its install base of physicians. It also offers anesthesia services. CRH Medical Corporation is headquartered in Vancouver, Canada. “

Corvus Pharmaceuticals (NASDAQ:CRVS) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Corvus Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of immuno-oncology therapies to harness the immune system to attack cancer cells. Its products include CPI-444, Adenosine production inhibitor, Adenosine A2B antagonist and Interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. Corvus Pharmaceuticals, Inc. is based in Burlingame, California. “

Carriage Services (NYSE:CSV) was downgraded by analysts at Zacks Investment Research from a strong-buy rating to a hold rating. According to Zacks, “Carriage Services, Inc. is a leading provider of death care services and products in the United States. Carriage provides a complete range of services relating to funerals, burials and cremations, including the use of funeral homes and motor vehicles, the performance of cemetery interment services and the management and maintenance of cemetery grounds. They also sell related products and merchandise including caskets, burial vaults, garments, cemetery interment rights, stone and bronze memorials, as well as other items. “

Receive News & Ratings for COCA COLA AMATI/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for COCA COLA AMATI/ADR and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Benz  Price Down 21.8% This Week
Benz Price Down 21.8% This Week
Ethan Allen Interiors Inc.  Expected to Post Quarterly Sales of $198.60 Million
Ethan Allen Interiors Inc. Expected to Post Quarterly Sales of $198.60 Million
Insider Selling: Sinclair Broadcast Group Inc  Director Sells 13,250 Shares of Stock
Insider Selling: Sinclair Broadcast Group Inc Director Sells 13,250 Shares of Stock
Chesapeake Gold  Reaches New 1-Year Low at $1.50
Chesapeake Gold Reaches New 1-Year Low at $1.50
Document Security Systems, Inc.  Sees Large Growth in Short Interest
Document Security Systems, Inc. Sees Large Growth in Short Interest
Incent Price Hits $0.19 on Major Exchanges
Incent Price Hits $0.19 on Major Exchanges


 
© 2006-2019 Zolmax.